Drug
Lunresertib clinical trials
Also written RP-6306.
Keep track of what changes. Save the lunresertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 2
Debiopharm International SA (2) · University Health Network, Toronto (1) · Canadian Cancer Trials Group (1)
Often tested with
Tested in the same studies.
Carboplatin (1) · Paclitaxel (1) · Gemcitabine (1) · Niraparib (1) · Fulvestrant (1) · Camonsertib (1) · CFI-402257 (1) · Ocifisertib fumarate (1)
Studies
Open first, then newest update. How each study uses lunresertib is read from its arms, and is right about nine times in ten.
Testing it · 4
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT05601440Written as RP-6306
- Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine CancerActive, not recruitingPhase 1University Health Network, TorontoNCT06107868Written as RP-6306
- Study of RP-6306 With FOLFIRI in Advanced Solid TumorsTerminatedPhase 1Debiopharm International SANCT05147350Written as RP-6306 (oral PKMYT1 inhibitor)
- Study of RP-6306 With Gemcitabine in Advanced Solid TumorsTerminatedPhase 1Debiopharm International SANCT05147272Written as RP-6306 (oral PKMYT1 inhibitor)
Given in every arm · 2 — lunresertib is usual care beside what is tested
- Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid TumorsRecruitingPhase 1Debiopharm International SANCT04855656Written as Lunresertib
- RP-6306 in Patients With Advanced CancerCompletedPhase 2Canadian Cancer Trials GroupNCT05605509Written as RP-6306
Codes
What other systems call lunresertib · ClinicalTrials.gg INT017368
- UNII (FDA) N95U3A7N57LUNRESERTIBOne source FDA
- NCI Thesaurus C179323LunresertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | N95U3A7N57 | LUNRESERTIB | One source FDA |
| NCI Thesaurus | C179323 | Lunresertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.